JP2024524870A5 - - Google Patents
Info
- Publication number
- JP2024524870A5 JP2024524870A5 JP2023575640A JP2023575640A JP2024524870A5 JP 2024524870 A5 JP2024524870 A5 JP 2024524870A5 JP 2023575640 A JP2023575640 A JP 2023575640A JP 2023575640 A JP2023575640 A JP 2023575640A JP 2024524870 A5 JP2024524870 A5 JP 2024524870A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- sequence number
- encoded
- identity
- aforementioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163202373P | 2021-06-08 | 2021-06-08 | |
| US63/202,373 | 2021-06-08 | ||
| PCT/US2022/032527 WO2022261113A2 (en) | 2021-06-08 | 2022-06-07 | Anti-gal3 antibodies and methods of use for insulin resistance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524870A JP2024524870A (ja) | 2024-07-09 |
| JP2024524870A5 true JP2024524870A5 (enExample) | 2025-06-17 |
Family
ID=84426396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575640A Pending JP2024524870A (ja) | 2021-06-08 | 2022-06-07 | 抗ｇａｌ３抗体およびインスリン抵抗性に使用する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220411514A1 (enExample) |
| EP (1) | EP4352105A4 (enExample) |
| JP (1) | JP2024524870A (enExample) |
| CN (1) | CN117897406A (enExample) |
| WO (1) | WO2022261113A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| CN117897406A (zh) * | 2021-06-08 | 2024-04-16 | 真和制药有限公司 | 抗gal3抗体及其用于胰岛素抵抗的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3125908A4 (en) * | 2014-03-10 | 2017-11-15 | La Jolla Pharmaceutical Company | Compositions and methods for treating kidney disorders |
| CN111032039B (zh) * | 2017-08-03 | 2024-03-26 | 卡莱克汀科学有限责任公司 | 用于预防和治疗医学障碍的化合物及其用途 |
| KR20210124308A (ko) * | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) * | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| CN117897406A (zh) * | 2021-06-08 | 2024-04-16 | 真和制药有限公司 | 抗gal3抗体及其用于胰岛素抵抗的方法 |
-
2022
- 2022-06-07 CN CN202280056135.2A patent/CN117897406A/zh active Pending
- 2022-06-07 WO PCT/US2022/032527 patent/WO2022261113A2/en not_active Ceased
- 2022-06-07 US US17/834,703 patent/US20220411514A1/en active Pending
- 2022-06-07 EP EP22820905.2A patent/EP4352105A4/en active Pending
- 2022-06-07 JP JP2023575640A patent/JP2024524870A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020169173A5 (enExample) | ||
| AU2012338733B2 (en) | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| RU2005115477A (ru) | Нейтрализующие антитела против gdf-8 и их применение | |
| KR102349370B1 (ko) | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 | |
| JP2021526534A5 (enExample) | ||
| JP2022546454A5 (enExample) | ||
| JP2008529489A5 (enExample) | ||
| JP2023526224A (ja) | がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用 | |
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| CN106794233A (zh) | 与肺动脉高压的治疗有关的组合物和方法 | |
| KR20240040090A (ko) | 항-dll3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도 | |
| JP2009519895A5 (enExample) | ||
| RS64060B1 (sr) | Antitelo na anti-adrenomedulin (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za sprečavanje ili smanjenje disfunkcije organa ili insuficijencije organa kod pacijenta koji ima hroničnu ili akutnu bolest ili akutno stanje | |
| WO2019201133A1 (zh) | 神经生长因子的单克隆抗体及其编码基因和应用 | |
| JP2024520202A5 (enExample) | ||
| JP2023511963A5 (enExample) | ||
| BR112020005682A2 (pt) | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) | |
| CN116444667B (zh) | 一种靶向gdf15的全人源抗体及其应用 | |
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| JP2023537078A5 (enExample) | ||
| JP7210612B2 (ja) | 抗ａベータ抗体及びその使用 | |
| JP7777071B2 (ja) | 抗α－シヌクレインモノクローナル抗体およびその使用法 | |
| JP2024522076A5 (enExample) | ||
| CN117815387A (zh) | Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物 | |
| CN111808196B (zh) | 抗pd-1抗体及其用途 |